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Two abundant classes of mobile elements, namely
Alu and L1 elements, continue to generate new retro-
transposon insertions in human genomes. Estimates
suggest that these elements have generated millions
of new germline insertions in individual human
genomes worldwide. Unfortunately, current technol-
ogies are not capable of detecting most of these
young insertions, and the true extent of germline
mutagenesis by endogenous human retrotranspo-
sons has been difficult to examine. Here, we describe
technologies for detecting these young retrotranspo-
son insertions and demonstrate that such insertions
indeed are abundant in human populations. We
also found that new somatic L1 insertions occur at
high frequencies in human lung cancer genomes.
Genome-wide analysis suggests that altered DNA
methylation may be responsible for the high levels
of L1 mobilization observed in these tumors. Our
data indicate that transposon-mediated mutagen-
esis is extensive in human genomes and is likely to
have amajor impact on human biology and diseases.
INTRODUCTION
Alu and L1 retrotransposons are two abundant classes of human
mobile elements. With each passing generation, Alu and L1
elements ‘‘jump’’ to new genomic locations through the process
of germline retrotransposition, thereby expanding the number ofelement copies in our genomes (Ostertag and Kazazian, 2001;
Batzer and Deininger, 2002). Some Alu and L1 insertions, termed
‘‘private’’ insertions, have been generated so recently that they
are found in only a single individual (Mills et al., 2007). Estimates
suggest that up to 600 million of these private germline insertions
have been generated in personal human genomes on a world-
wide basis (Kazazian, 1999; Li et al., 2001; Brouha et al., 2003;
Cordaux et al., 2006; Mills et al., 2007; Xing et al., 2009). This
is an impressive mutagenesis of the human genome and is
collectively equivalent to one insertion for every 5 bp of chromo-
somal DNA.
Although transposon mutagenesis is not expected to be
a totally random process in the human genome, this level of
mutagenesis clearly would have a major impact on human
biology. However, it is presently unclear whether new insertions
are indeed produced in the germline as frequently as these esti-
mates suggest. Unfortunately, transposon mutagenesis has
been difficult to study in humans because we lack efficient
assays for detecting new and otherwise young retrotransposon
insertions. As a consequence, most of the transposon insertions
that have been detected to date are common or fixed insertions
that have been discovered by genome sequencing projects
(Lander et al., 2001; Venter et al., 2001), and relatively few rare
insertions have been discovered (Wang et al., 2006). Arguably,
new and otherwise young insertions are much more interesting
than common alleles, as purifying selection has not yet fully
acted upon these young alleles and they are much more likely
to disrupt genes. Thus, the full extent of germline mutagenesis
by endogenous retrotransposons remains relatively unexplored
in humans.
For the same reason, it has been difficult to determine whether
human retrotransposons are actively ‘‘jumping’’ in somaticCell 141, 1253–1261, June 25, 2010 ª2010 Elsevier Inc. 1253
Figure 1. Strategy to Sequence Retrotrans-
poson Insertion Junctions
The approaches that were used to sequence retro-
transposon insertion junctions are depicted: ABI
(left side) and pyrosequencing (right side). The
‘‘transposon’’ is either L1-Ta or Alu. Human
genomic DNA is digested with a restriction endonu-
clease and ligated to a linker. The linker is partially
double-stranded with a 30 amine group on the short
strand. This prevents amplification of random
genomic DNA from the linker primers. Amplification
only occurs if there is extension from the
transposon-specific primer. This completes the
double-stranded linker and creates the sequence
for the linker-specific primer to anneal to, thus
allowing the PCR reaction to proceed. Left side:
ABI sequencing. After an initial PCR amplification,
a second round of PCR is performed with nested
primers. Second-round PCR products are cloned
into pBLUESCRIPT using a restriction site in the
nested retrotransposon primer and another restric-
tion site in the linker. Resulting colonies are sent for
ABI Sanger capillary sequencing. Right side: pyro-
sequencing. After an initial PCR amplification,
a second PCR is performed with nested primers.
The retrotransposon nested primer contains the
‘‘A’’ adaptor sequence for 454 sequencing,
whereas the linker-specific primer contains an
8 bp unique barcode for each sample and the ‘‘B’’
adaptor sequence. Samples are pooled in equal
molar ratios for emulsion PCR with beads binding
only the ‘‘A’’ end. Thus sequencing occurs from
the ‘‘B’’ end only, avoiding possible problems
with sequencing through the poly(A) tail of L1.
A similar approach was used with Alu except the
50 junctions were amplified and sequenced.
Please see Experimental Procedures and
Extended Experimental Procedures for additional
details.tumor genomes. Such retrotransposons are, for the most part,
silent in normal somatic tissues (Kano et al., 2009). Thus, if
they were reanimated, these elements might help to drive tumor-
igenesis or further destabilize an already unstable cancer
genome. Several lines of evidence suggest that endogenous
retrotransposons might be derepressed in human somatic
tumors as a consequence of altered DNA methylation (Bestor,
1998; Borc’his and Bestor, 2004; Howard et al., 2008). However,
it remains unclear whether these elements are, in fact, mobilized
at elevated frequencies in tumors. Three L1 insertion candidates
have been reported in human tumors (Morse et al., 1988; Miki
et al., 1992; Liu et al., 1997) (Figure S1 available online), but
only one of these insertions has all of the hallmark features of
a true somatic retrotransposition event (Miki et al., 1992; Fig-
ure S1). Thus, as above, the extent of transposon mutagenesis
in human somatic tumors remains unclear.
As a step toward investigating transposon mutagenesis in
normal and cancer genomes, we have developed ‘‘trans-
poson-seq’’ technologies that can detect new and otherwise
young retrotransposon insertions in humans. Our experiments
reveal that young retrotransposon insertions indeed are highly
abundant in personal human genomes and extend far beyond1254 Cell 141, 1253–1261, June 25, 2010 ª2010 Elsevier Inc.the number of insertions that have been detected previously.
We also found that de novo L1 insertions occur at high frequen-
cies in human lung tumor genomes. Thus, transposon-mediated
mutagenesis is extensive in human genomes and is likely to have
a major impact on human biology and diseases.
RESULTS
‘‘L1-Seq’’ Assays for Detecting Germline L1 Insertions in
Personal Genomes
Our goal was to develop an efficient assay that, ideally, could
detect a new retrotransposon insertion anywhere in the 3 billion
bp haploid human genome. We began by examining traditional
gel-based L1 display assays with the hope of deriving an
improved assay that could tackle this challenge (Sheen et al.,
2000; Ovchinnokov et al., 2001; Badge et al., 2003; Figure 1).
These linker-mediated PCR assays take advantage of specific
sequence changes that are present in the youngest L1 elements
(the Ta elements; Skowronski et al., 1988; Boissinot et al., 2000)
to amplify large collections of L1-Ta junction fragments from
the human genome (Figure 1). Although multiple laboratories
have successfully used L1 display to identify novel L1 insertions,
Table 1. Transposon-Seq Results
Sequencing Strategy Sample Description Retrotransposon Reads Mapped
Distinct
Retrotransposons
Previously
Unknown
PCR
Validated
ABI capillary
sequencing
Pools of diverse human DNA
and tumor-derived cell line DNA
L1 4600 3795 785 152 64/66 (97%)
Pyrosequencing Lung tumor and adjacent normal
lung DNA; brain tumor and
matched normal blood DNA
L1 286,126 50,532 1,389 650 162/182 (89%)
Pyrosequencing Brain tumor and matched
normal blood DNA
Alu 35,022 22,338 3799 403 53/56 (95%)
The Alu and L1 transposon-seq data for this study are summarized. Please see Table S1, Table S2, Table S3, Table S4, Experimental Procedures, and
Extended Experimental Procedures for supporting data and details.such assays are inherently low-throughput and also have high
false-positive rates (Sheen et al., 2000; Ovchinnokov et al.,
2001; Badge et al., 2003). After attempting several modifications
of this approach, we found that L1 display could be significantly
improved by applying high-throughput DNA sequencing directly
to the initial collections of L1-Ta junction fragments that are
generated by these assays. We then applied informatics filtering
to the resulting datasets to eliminate false positives and to iden-
tify high-probability L1-Ta insertion candidates.
We explored both ABI capillary sequencing and 454 pyrose-
quencing to recover large collections of L1 insertion junctions
from our linker-mediated PCR experiments (Figure 1). In our first
‘‘L1-seq’’ experiment, we examined 4600 PCR junction frag-
ments by cloning them into plasmids and sequencing them
with ABI Sanger capillary sequencing (Figure 1, left and Table 1).
The PCR junction fragments for this experiment were generated
from the genomes of (1) 24 ethnically diverse humans (the Coriell
Polymorphism Discovery Panel; Collins et al., 1999), (2) 14 addi-
tional diverse humans from the Coriell repository, and (3) 8 ATCC
cell lines that were derived from human tumors (Please see
Experimental Procedures and Extended Experimental Proce-
dures). This approach was highly successful and yielded 785
distinct L1 insertions from the genomes examined (Table 1 and
Table S1). After comparing these insertions to the reference
human genome sequence and to previously discovered retro-
transposon insertion polymorphisms (deposited to dbRIP, a
database of human retrotransposon insertion polymorphisms;
Wang et al., 2006), 152 novel L1 insertion polymorphisms were
identified (Table 1 and Table S1).
To investigate these L1 insertions further, we performed
a series of PCR validation studies (Table 1 and Table S1). These
studies confirmed that our trace data were highly accurate (with
a validation rate of 97%) and also confirmed that our collections
include both common and rare L1 alleles (Table S1 and Figure 2).
In contrast to dbRIP, which predominantly contains common L1
alleles (Wang et al., 2006), 30% of the L1 insertions discovered
from our ABI sequencing experiments had minor allelic frequen-
cies (MAFs) of 5% or below (compare Figures 2D and 2E). Like-
wise, follow-up PCR experiments revealed that 9/47 (19.1%) of
the rare insertions were found only in a single human in our study
(Figure 2C; MAF < 1.1%). Similar results were obtained with
a second set of experiments that were conducted with pyrose-
quencing (Figure 2F, see below). Thus, although rare L1 inser-tions have gone largely undetected previously, our data clearly
indicate that such insertions are abundant in human populations.
Frequent Somatic L1 Insertions in Lung Tumor Genomes
Despite the fact that we examined only eight cell lines from
human tumors in this initial experiment (leukemias, breast, and
lung cancers), we identified what appeared to be a somatic L1
insertion in one of these cell lines. In particular, we identified
an L1 insertion in the lung-tumor derived cell line NCI H1395
that was absent from the matched normal DNA from the same
patient’s blood (Figure 3A). These results suggested the possi-
bility that lung tumor genomes might support high levels of L1
mobilization. To explore this question further, we examined in
parallel from the same tissue sources DNA samples isolated
from 20 primary non-small cell lung cancers and 20 matched
normal adjacent tissues. Because L1 is highly active in both
the mouse brain (Moutri et al., 2005) and human neural stem cells
(Coufal et al., 2009), we also examined 10 human brain tumors
(5 glioblastoma and 5 medulloblastoma) and 10 matched blood
leukocyte controls to determine whether somatic L1 retrotrans-
position might be occurring in these tumors as well.
We began by retooling the L1-seq assay for 454 pyrosequenc-
ing, as this would greatly increase the throughput of the
assay and allow us to examine these 60 samples with greater
sequencing depth and efficiency (Figure 1). The standard 454
A and B primers were incorporated into the assay, and the
PCR products were sequenced solely from the B end to avoid
possible artifacts of sequencing through the L1 poly(A) tails
(Figure 1, right). A similar Alu-seq assay was developed to detect
young Alu insertions. For this assay, sequencing was performed
from the 50 end of Alu. In each case, 20 samples were combined
into a single sequencing experiment (10 tumor and 10 matched
controls), using a bar-coding strategy (Hamady et al., 2008)
that allowed us to assign a given sequence to a specific sample
from the pool (Figure 1, right). Like the ABI L1-seq assay dis-
cussed above, this approach was highly successful and yielded
1389 distinct L1 insertions in the 60 samples that were examined
(Table 1 and Table S2). After comparing these L1 candidates to
the reference human genome and to dbRIP (Wang et al., 2006),
650 novel L1 insertions were identified (Table 1 and Table S2).
Forty-five percent of these L1 alleles had MAFs % 5% (Figures
2B and 2F). Moreover, 93% of the genomes had at least one
rare L1 insertion that was present in only a single human in ourCell 141, 1253–1261, June 25, 2010 ª2010 Elsevier Inc. 1255
Figure 2. Characterization of Novel L1 Elements
(A) For both ABI sequencing and pyrosequencing experiments, L1 elements that were not present in the human reference sequence (hg18) were compared with
L1 polymorphisms that have been deposited in dbRIP (Wang et al., 2006). The Venn diagram depicts the relationships between our candidates and L1 insertions
that have been deposited to dbRIP but are absent from hg18. Note the minimal overlap between our datasets and the L1 polymorphisms in dbRIP, indicating that
our L1-seq method has recovered many novel insertions. Our assays predominantly detected L1-Ta and pre-Ta elements (Table S5).
(B) Correlation of estimated and previously determined allelic frequencies. For the pyrosequencing experiment, allelic frequencies were estimated using
sequence data and were compared to known allelic frequencies of polymorphic L1 elements (n = 63).
(C) A subset of L1 elements that appeared to be ‘‘singletons’’ based on their presence in a single individual (from sequence data) and absence from hg18 and
dbRIP were verified by PCR in pools of diverse human DNA. The Individual lane is the individual from whom the L1 was initially sequenced.Pool lanes contain DNA
from 15 diverse humans. Chimp is Coriell #NA03448A and Negative is a control PCR with no template.
(D) Histogram of allelic frequencies for polymorphic L1’s in dbRIP (Wang et al., 2006). Allelic frequency data were extracted from dbRIP (n = 153).
(E) Allelic frequencies of L1’s identified by ABI Sanger dideoxy sequencing. Allelic frequencies were determined by PCR in a panel of 46 diverse individuals
(n = 46).
(F) Allelic frequencies of L1’s identified by pyrosequencing. Allelic frequencies were determined as depicted in (B) (n = 650).study. An additional 403 novel Alu insertions were identified
from the Alu assay, including both common and rare Alu alleles
(Table 1 and Table S3). Like our ABI results outlined above, these
pyrosequencing data clearly demonstrate an abundance of rare
retrotransposon insertions in the genomes examined.
We hypothesized that some of these low-frequency alleles
might have been caused by new somatic retrotransposition
events in the tumor genomes. Thus, we screened low-frequency
alleles with PCR assays and identified nine tumor-specific
somatic L1 insertions (Figure 3A). Most of the remaining insertions
were considered to be germline insertions because they were
found in just the normal tissue (or both tissues) of a patient or
were found in multiple humans. All nine of the somatic insertions
were present in the tumor tissues but were completely absent1256 Cell 141, 1253–1261, June 25, 2010 ª2010 Elsevier Inc.from the adjacent normal tissues (Figure 3A). Eight of the nine
somatic insertions were further confirmed by cloning the PCR
junction fragments that were amplified from the tumor DNAs
and sequencing them (the ninth could not be sequenced because
both the original DNA and the PCR products from the tumor
tissue became depleted; data not shown). All of the somatic L1
insertions were found in the lung tumors, and no somatic inser-
tions were identified in the brain tumors that were examined
(data not shown). Likewise, no somatic Alu insertions were iden-
tified in the brain tumors that were examined (data not shown).
Although additional studies will be necessary to determine
the full spectrum of cancer genomes that are permissive for
Alu and L1 mobilization, these data indicate that lung tumor
genomes are highly permissive for L1 mobilization. The nine
Figure 3. PCR Validation of Somatic Inser-
tions and Identification of a Hypomethyla-
tion Signature in Tumors with New L1 Inser-
tions
(A) Nine somatic L1 insertions were identified by
screening low-frequency L1 insertions that were
identified initially from our pyrosequencing data
(Table S2) with PCR assays. Shown here are those
verified as somatic insertions by their presence in
the tumor tissue and absence from adjacent
normal tissue. Negative lanes are control PCRs
with no template. Primers flanking the putative
insertion sites were used to amplify the preinser-
tion alleles. Primers within the 30 end of an L1
consensus sequence and downstream of the
putative insertion sites were used to verify the
presence of each L1. Anonymous patient identi-
fiers are on the left. NCI-H1395 is a tumor-derived
cell line matched with its normal B-lymphocyte
control (both from ATCC). The three somatic L1
insertion candidates that have been reported
previously in the literature are shown in Figure S1.
(B) The methylation statuses of the 20 lung tumor
and normal adjacent tissues used in the pyrose-
quencing experiment were analyzed by Illumina In-
finium analysis. Fifty-nine probes were identified
whose changes in methylation status in the tumor
specimens relative to matched normal tissues
were tightly correlated with somatic L1 retrotrans-
position (Table S6). The six tumors that were posi-
tive for somatic L1 insertions (blue) clustered
together along with one of the remaining tumor
samples (i.e., sample 119), which did not have a somatic L1 insertion (orange). Tumor ANCO119 (seventh from the left) clustered with the L1-positive tumors
but lacked an L1 insertion, suggesting that it might also have an L1-permissive state. This signature expands to 1928 correlated probes if tumor 119 is included
in the L1 permissive class and the least correlated tumor of the six L1-positive tumors (ANCO106) is shifted to the L1-negative class (see Experimental Procedures).somatic L1 insertions described above (Figure 3A) were found in
6 of the 20 lung tumors that were examined. Thus, an impressive
30% of the lung tumors had at least one new L1 insertion and
some tumors had two or even three new L1 insertions. Given
that our assay recovers insertions from only a fraction of the
genome, this 30% measurement is likely to represent the lower
boundary of somatic L1 insertion frequencies in lung tumor
genomes (see Experimental Procedures). As L1 is mostly silent
in normal somatic tissues, this rate suggests that lung tumors
behave like germline or early embryonic tissues with respect to
L1 mobilization (Borc’his and Bestor, 2004; Moutri et al., 2005;
Coufal et al., 2009; Kano et al., 2009).
A Methylation Signature in L1-Permissive Tumors
Genomic DNA methylation is often altered in human lung tumors
(Daskalos et al., 2009) and is also thought to play a role in sup-
pressing retroelements (Bestor, 1998; Borc’his and Bestor,
2004; Howard et al., 2008). Thus, we next used the Illumina Infin-
ium platform to examine the genome-wide methylation status of
27,578 CpG dinucleotides in our lung tumor specimens. In order
to study the relationship between DNA methylation and somatic
L1 retrotransposition, patient samples were divided into two
groups: (1) those with tumor-specific somatic L1 insertions and
(2) those without such insertions (Figure 3B). On the basis of
this classification, 59 probes were identified for which the change
in DNA methylation status between the tumor and adjacentnormal tissue from the same patient was significantly correlated
with the L1 retrotransposition potential of the tumors (Table S6;
randomly permuted datasets averaged only 1.5 significantly
correlated probes). Unsupervised hierarchical clustering of the
samples based on these 59 probes revealed a dendrogram con-
sisting of two distinct sample groups (Figure 3B). All six patients
exhibiting somatic L1 insertions were clustered together into one
branch whereas 13/14 of the patients that lacked somatic inser-
tions were clustered into a separate branch. Even though L1
insertions were not detected in tumor DNA from patient 119,
this DNA was more related to the insertion-positive group on
the basis of the differential methylation status of the 59 probes
(see Experimental Procedures). This observation suggests (1)
that the tumor DNA from patient 119 harbors an existing L1
insertion that was not detected, or (2) that this patient’s tumor
exhibited an environment that was permissive for L1 retrotrans-
position but had not yet produced a new L1 insertion. Overall,
these data reveal a methylation signature that distinguishes L1-
permissive lung tumors from non-L1-permissive tumors. Inter-
estingly, all correlated probes were hypomethylated to varying
degrees in the tumors relative to the matched normal tissues.
DISCUSSION
Our transposon-seq methods have revealed that rare germline
retrotransposon insertions are present in virtually all personalCell 141, 1253–1261, June 25, 2010 ª2010 Elsevier Inc. 1257
genomes in human populations and extend far beyond the inser-
tions that have been identified in the reference human genome
(Figures 2E and 2F). By applying our assays to the genomes of
76 diverse humans, we identified a total of 1145 new Alu and
L1 insertions that had not been reported previously (Tables S1,
Table S2, and Table S3; Lander et al., 2001; Wang et al.,
2006). A surprisingly large percentage of these insertions were
rare. This fact is most clearly demonstrated by the relatively large
number of rare insertions (with MAFs % 5%) that were discov-
ered in our study (Figures 2E and 2F) compared to the small
number of rare insertions that are present in dbRIP (Figure 2D).
Because we confirmed that our assays predominantly detect
the very youngest and most active retrotransposons in the
human genome (Table S5 and Experimental Procedures), most
of these rare insertions are likely to have been generated very
recently. Despite the fact that entirely different human popula-
tions were examined, we identified some of the very same full-
length active L1 elements that were identified by Beck et al. in
the accompanying manuscript (Beck et al., 2010 [this issue of
Cell]). Nevertheless, most of the insertions in the two datasets
were detected by only one of the groups, suggesting that
many additional retrotransposon insertions will be discovered
in personal human genomes. Consistent with this idea, peaks
of structural variation have been noted that correlate with Alu
and L1 elements in the Watson genome and in other human
genomes (Bennett et al., 2004; Mills et al., 2006; Levy et al.,
2007; Korbel et al., 2007; Wheeler et al., 2008; Xing et al., 2009).
The 1145 novel Alu and L1 insertions that were identified in our
study of 76 humans were distributed throughout the human
genome on all 24 chromosomes. A large fraction of these inser-
tions (391/1145 or 34.2%) were located within known RefSeq
genes (Tables S1, Table S2, and Table S3). Ten of the 1145 inser-
tions (0.9%) were located within exons and the remaining 381
insertions were located within introns (Tables S1, Table S2,
and Table S3). This percentage of insertions in exons (0.9%)
approaches the percentage of the genome that is occupied by
exons (1.5%; Lander et al., 2001), indicating that Alu and L1
elements can effectively mutagenize exons. Insertions in introns
also can affect gene function by causing exon skipping or by
influencing transcript elongation, splicing, or polyadenylation
(Ostertag and Kazazian, 2001; Batzer and Deininger, 2002).
Thus, young retrotransposon insertions in exons and introns
are likely to have a major impact on gene function.
Our results provide strong support for a neutral theory (Kimura
and Ota, 1971) model in which large pools of new germline
insertions are continuously generated in personal genomes.
Over time, the majority of these alleles, which are expected to
be neutral, are likely to be eliminated by genetic drift. However,
detrimental alleles also would be expected to be produced in
these pools (Boissinot et al., 2001), including insertions in the
exons of known genes and other functional DNA sequences. In
fact, several dozen disease-causing transposon insertions
have been identified in genes to date (reviewed in Ostertag
and Kazazian, 2001; Batzer and Deininger, 2002; Mills et al.,
2007) and our data suggest that many more will be found.
We also provide strong evidence that somatic L1 retrotranspo-
sition occurs frequently in human lung tumors. Although the
hypothesis that retrotransposons might play a role in driving1258 Cell 141, 1253–1261, June 25, 2010 ª2010 Elsevier Inc.tumorigenesis has been around for several years (Bestor,
1998), it has been difficult to test in humans. Our transposon-
seq technologies now reveal that transposons indeed are mobi-
lized at high frequencies in at least one type of human tumor
(Figure 3A). Moreover, L1-permissive tumors had a specific
hypomethylation signature (Figure 3B), suggesting that altered
DNA methylation might be responsible for the unusual levels of
L1 mobilization that were observed in these tumors (see below).
Once reactivated, L1 could be envisioned to mutate genes
that are involved in cancer pathways (Dupuy et al., 2005; Collier
et al., 2005) or to facilitate deletions and other large-scale chro-
mosomal rearrangements that are commonly found in human
tumors (Pearson and Rowley, 1985; Xing et al., 2009). Thus,
high levels of L1 mobilization would further destabilize an
already unstable cancer genome. Overall, our experiments in
both normal and cancer genomes provide compelling evidence
that human transposons are potent endogenous mutagens
that continue to drive the evolution of human genomes.
Our genome-wide methylation analysis revealed a specific
hypomethylation signature that was strongly correlated with
the six L1-permissive lung tumors that were identified in our
study (Figure 3; Table S6). We examined the genomic regions
surrounding the 59 highly correlated probes and determined
that no modern, full-length L1-Ta, Pre-Ta, or L1-PA2 elements
were located near these probes in the haploid reference
human genome. However, this does not rule out a model in
which master L1-Ta elements are derepressed as a conse-
quence of hypomethylation. The hypomethylation signature
that is captured by our 59 probes could represent a broader
hypomethylation state that releases master L1 elements from
constraint at other genomic sites. Additional statistical modeling
of our methylation data supports this possibility and indicates
that our 59-probe signature is likely to represent a much larger
signature of 1928 probes that are correlated with L1 retrotrans-
position (Experimental Procedures). These results suggest that
specific hypomethylation patterns may influence the mobiliza-
tion of retrotransposons in human genomes. The relationship
between these patterns of hypomethylation and other forms of
genomic instability in human tumors is presently unclear.EXPERIMENTAL PROCEDURES
DNA Samples
The following genomic DNA samples were obtained from the Coriell Repository
and were used to prepare L1-seq libraries: NA15029, NA15036, NA15213,
NA15215, NA15223, NA15224, NA15236, NA15510, NA15221, NA15227,
NA15385, NA15056, NA15590, NA15038, NA15245, NA15072, NA15144,
NA15216, NA15226, NA15242, NA15268, NA15324, NA15386, NA15594,
NA11200, NA11776, NA10970, NA10968, NA10975, NA10492, NA10469,
NA13820, NA13619, NA10540, NA11377, NA11321, NA13597, and NA13607.
The following genomic DNA samples were obtained from the ATCC (cancer-
derived cell lines and one normal control): 45500 (HL-60), 45502 (THP-1),
45506 (K-562), 45508 (NCI-H1395), 45510 (NCI-BL1395), 45516 (MDA-MB-
175), 45518 (MDA-MB-231), 45522 (BT-483), 45532 (ZR-75-30).
Patient-derived glioblastoma and medulloblastoma tumors and matched
blood leukocytes were obtained from the Emory University School of Medicine
Tissue Procurement and Banking Service. Samples were snap-frozen by
dipping them in a container with isopentane cooled with liquid nitrogen. The
samples then were transferred to cryovials and stored in liquid nitrogen.
Genomic DNA was extracted from 25 mg of tissue using the DNeasy Tissue
Kit (QIAGEN). Twenty snap-frozen non-small cell lung cancer specimens
(16 adenocarcinomas, 4 squamous cell carcinomas) and paired adjacent
normal tissues were obtained from the Emory University School of Medicine
Tissue Procurement and Banking Service. Genomic DNA was extracted
from 15 mg of snap-frozen lung tissues using the DNeasy Tissue Kit (QIAGEN).
Population Distributions
In many cases, specific information was available regarding the ethnicities,
genders, and ages of the humans that were examined in our study. A complete
listing of all available population data can be found in the Table S7. Lung tumor
specimens were de-identified as a condition of Emory University’s Institutional
Review Board approval, and we do not have further information beyond the
pathology at diagnosis. Likewise, specific information for the polymorphism
discovery panel (Coriell) is de-identified and we know only that the 24 humans
represent a diverse human population (see Collins et al., 1999).
Sequencing Platforms
We explored two different sequencing platforms to identify new transposon
insertions in personal genomes. We began with traditional ABI Sanger
sequencing to characterize L1-Ta insertion junctions. This approach provided
high-quality, long reads that originated within L1 elements and extended
through the poly(A) tails into adjacent genomic sequences. We also explored
454 sequencing because it is relatively less expensive, particularly when
used together with a bar coding and pooling strategy that analyzes multiple
samples (Hamady et al., 2008). Despite the fact that the 454 reads are not
as long as those that are produced by ABI sequencing, the full junction
sequences were usually recovered with 454 reads, including poly(A) tails
and other transposon sequences. Reads that contain this information gener-
ally have higher validation rates than reads that do not span insertion junctions.
Finally, we also considered using the Illumina platform and other next-gen
sequencers. Illumina has shorter reads than ABI and 454, and we decided
not to explore this platform because it would not yield junction sequences.
However, the higher read densities that are achieved with the Illumina platform
may provide some advantages over the ABI and 454 approaches.
Targeted Sequencing of Retrotransposon Insertion Junctions
Linker-mediated PCR methods were adapted from Siebert et al. (1995). In
brief, genomic DNA was digested with restriction endonucleases and then
ligated to linkers. Purified ligation products were used as templates for PCR
with linker-specific and transposon-specific primers (please see Table S8
for a list of the primers that were used for transposon-seq). A second PCR
reaction was performed with nested primers to increase the specificity of the
reaction. For ABI sequencing experiments, the PCR products were cloned
into pBLUESCRIPT (Stratagene) using restriction sites that were incorporated
into the nested primers. Individual colonies were used to inoculate LB-Amp
(freezing) medium in 96-well plates and these (frozen) cultures were sent to
Agencourt Bioscience (Beverly, MA, USA) for ABI capillary sequencing. For
pyrosequencing experiments, nested primers contained adaptor sequences
and 8 bp barcodes (please see the Extended Experimental Procedures and
Table S8). Samples were pooled in equal molar ratios and gel-purified to
remove small, uninformative products. Purified samples were then sent to
the University of Florida Interdisciplinary Center for Biotechnology Research
or the Genomics Resource Center at the Institute for Genome Sciences for
emulsion PCR and Roche 454 pyrosequencing. Please see the Extended
Experimental Procedures for additional details.
Sequence Analysis and PCR Validation
FASTA sequences were parsed into A and B adapters, linker, barcode, retro-
transposon, and unique genomic sequences. Custom Perl scripts were devel-
oped to compare the sequences to the human genome (May 2006 build, hg18)
using BLAT (Kent et al., 2002). For L1, each nonredundant hg18 coordinate
was compared to the coordinates of known L1s using Galaxy (Taylor et al.,
2007) to determine whether an L1 element was located in the adjacent region
of the reference sequence. For Alu, sequences flanking the insertion site in
hg18 were used to query CAlu, a web-based Alu classifier (available at
http://clustbu.cc.emory.edu/calu/index.cgi) to determine whether the Alu
was present in the reference sequence. PCR validations were performed usingstandard protocols (see Extended Experimental Procedures). The primers that
were used for PCR validation studies are listed in Table S1 (ABI sequencing),
Table S4 (L1 pyrosequencing), and the Table S9 (Alu pyrosequencing).
Evaluation of Transposon Families and Subfamilies
We confirmed that our assays are detecting the very youngest retrotransposon
subfamilies in the human genome as follows. Our assays detect both existing
copies of retrotransposons that have been documented in the reference
haploid human genome as well as new insertions at other sites. When an
existing copy is detected in the reference genome, we can determine the
family or subfamily of that element from its genomic sequence. Thus, traces
that map to existing copies in the genome serve as internal controls for our
experiments and allow us to estimate the percentage of young elements that
are detected. For our 454 L1-Ta experiments, 92.1% of the traces that map-
ped to existing elements in the genome mapped to L1-Ta elements and
another 5.2% of these traces mapped to pre-L1-Ta elements, which are also
very young. Thus, our assay is highly specific for L1-Ta and Pre-Ta elements,
and most of the elements detected (97.3%) belong to these two very young L1
classes (Table S5). Similarly, 93.1% of the L1 elements detected in our ABI
experiments belong to these two young classes (Table S5). We also confirmed
that our Alu assays are detecting young Alu elements: 94.6% of the traces that
mapped to existing elements detectedAluY elements and elements belonging
to some of the very youngestAlu Y subfamilies (Table S5).Alu Ya5 (64.1%),Alu
Y (11.2%), and other young Alu Ya subfamilies (16.9%) were the most
abundant elements detected. Thus, our assays are highly specific for the
very youngest retrotransposon families in the human genome.
Calculation of Assay Coverage and Efficiency
Our assay uses a reduced representation approach to detect new insertions
within a specific subset of restriction fragments in the human genome. For
example, we estimate that our approach samples 4.5 million of the 10.5
million MseI restriction fragments that are generated for our 454 L1-seq
assays. The same 4.5 million fragments are examined in all of the samples in
the assay, providing greater depth of coverage for this set of fragments. We
assume that we can detect an L1-Ta (or Alu) insertion if it occurs within
300 bp of an MseI restriction site. The reference human genome contains
216 L1-Ta elements that fall within 300 bp of an MseI site. This represents
approximately 43% of the 508 L1-Ta elements in the reference human genome
sequence. On this basis, we estimate that we can detect new insertions from
approximately 43% of the genome. Using these estimates, we determined that
we achieved an average of 3.13 coverage of the detectable L1-Ta insertion
junction fragments in our initial 454 experiments (please see Extended Exper-
imental Procedures and Table S10).
Our approach for examining the efficiency of our assay using the reference
haploid genome sequence is outlined as follows. We identified 51 fixed L1-Ta
elements that are located within 300 bp of an MseI restriction cleavage site.
As these elements are fixed in human populations (Myers et al., 2002) and are
expected to be present in all of the genomes examined, these elements serve
as internal controls for the efficiency of detection. We achieved an average of
72.3% detection of these 51 elements in our initial 454 L1-Ta experiments at
3.13 sequencing coverage (please see Extended Experimental Procedures
and Table S10). When the sequencing coverage was increased to 5.83
coverage, our efficiency increased to an average of 84% (please see Extended
Experimental Procedures and Table S10). Additional increases in sequencing
coverage beyond 3.13 to 5.83 are predicted to yield relatively small additional
increases in L1 discovery, as the redundancy of L1 detection also increases.
Further increases could be achieved by combining two or three restriction
enzymes in the assay, which would provide genome-wide coverage. Some
insertions will be difficult or impossible to recover with our assays. For example,
insertions that occur within the unsequenced portions of the human genome will
not be detected. Likewise, it can be difficult or impossible to map insertions that
fall within or near other transposon repeats. Thus, a fraction of the insertions in
a given genome will be refractory to detection with our methods.
Methylation Analysis
Genomic DNAs from 20 lung tumors and matched normal tissues were
bisulfite-modified and then used to perform genome-wide DNA methylationCell 141, 1253–1261, June 25, 2010 ª2010 Elsevier Inc. 1259
profiling with the Illumina Infinium Human Methylation 27 v1.0 platform. Probes
were identified for which the changes in methylation status between the
tumors and their matched normal adjacent tissues were correlated with
somatic L1 retrotransposition using the Quantitative Response feature within
the Significance Analysis of Microarrays (SAM) software package (Tusher
et al., 2001; see Extended Experimental Procedures). Differential methylation
data for significantly correlated probes were hierarchically clustered using
Cluster 3.0 (distance metrics: genes = Euclidean, arrays = Pearson; linkage =
average) and visualized with Java Treeview.
Statistical Modeling of Methylation Data
One of the L1-negative tumors (ANCO119) appeared to cluster with the six
L1-positive tumors based on the 59 differentially methylated probes, suggest-
ing that this might represent a tumor that is in fact permissive for retrotranspo-
sition but for which an L1 retrotransposition event had not yet been found
(Figure 3B; Table S6). To test this possibility quantitatively, we moved
ANCO119 into the L1-positive group and re-ran the Quantitative Response
feature using SAM. This increased the number of probes detected to 139 for
the expanded sample set, all of which were hypomethylated in the L1-positive
group of tumors relative to their corresponding normal tissues. As a control, we
ran 13 additional analyses, where, in each analysis, we similarly moved 1 of the
13 other L1-negative tumors into the L1-positive category. In all 13 of these
cases, this resulted in a significant decrease in the number of correlated
probes. Thus, unlike the other L1-negative tumors, the methylation status of
sample ANCO119 is more closely related to the L1-positive tumors.
Motivated by this finding, we performed additional analyses, where, in each
analysis, we moved one of these seven tumors (i.e., one of the six L1-positive
tumors or the ANCO119 tumor) into the L1-negative group. In all but one case,
this resulted in significantly fewer differentially methylated probes being corre-
lated with the L1-positive category. However, the additional step of moving
one of the L1-positive tumors, namely ANCO106, to the L1-negative category
resulted in a dramatic increase in the number of correlated probes detected (to
1928). Interestingly, again, all 1928 correlated probes were hypomethylated in
the L1-positive category of tumors relative to their normal tissue counterparts.
To determine the combination of 6 tumors out of 20 that gave the maximal
number of significantly correlated hypomethylated probes, we analyzed every
possible combination (n = 38,760) such that 6 tumors were placed in one cate-
gory and 14 in the other and re-ran the analysis. In every other combination, the
number of hypomethylated probes that correlated with these arbitrary tumor
partitionings was less than 1928. Thus, the profile obtained using the five
L1-positive tumors (ANCO103, ANCO104, ANCO105, ANCO110, ANCO118)
plus the one L1-negative tumor (ANCO119) corresponds to the optimal (six
tumor) hypomethylation signal in this dataset. The correlation between this
optimal hypomethylation profile and L1 retrotransposition is statistically signif-
icant: based on Fisher’s exact test the probability of having observed this in the
absence of such a correlation is p = 0.0022.
Statistical Analysis of Lung versus Brain Tumors
The fact that we detected nine new L1 insertions in 20 lung tumor samples but
none in 10 brain tumor samples suggested that tumor-specific retrotransposi-
tion might be more prevalent in lung tumors compared to brain tumors. To test
the hypothesis that the observed difference is merely due to chance variation,
we performed the following statistical analysis. The maximum likelihood esti-
mate for the frequency of a lung-tumor-specific L1 retrotransposition event
is 1.4 3 107. This is based on our observation of new insertions within 9 of
the approximately 66 million fragments that were implicitly tested within
20 lung tumor samples. Our estimate of implicit tests performed assumes (1)
that the 2.7 billion bp sequenced portion of the human genome contains
approximately 10.5 million fragments after digestion with a restriction enzyme
that cuts on average every 256 bp; (2) that we can detect insertions in43% of
these fragments; (3) that, among these, the average efficiency of detection is
72.3%; and (4) that as a result, 3.3 million independent tests were performed
per sample. Based on a binomial probability distribution where the total
number of tests is 33 million and the number of ‘‘successes’’ is zero, we
thus obtain a probability of 0.011 that we would have observed no tumor-
specific L1 retrotransposition events within the 10 brain tumor samples due
to chance alone. Given a significance cutoff of 0.05, we reject the null hypoth-1260 Cell 141, 1253–1261, June 25, 2010 ª2010 Elsevier Inc.esis and conclude that the frequency of L1 retrotransposition is different in
brain versus lung tumor samples. However, it is important to note that this
does not necessarily indicate that L1 mobilization is absent from brain tumors.
It remains possible that the rate of L1 mobilization is slightly lower in brain
tumors, or that we did not sample the most active brain tumor types in our
study.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, one
figure, and ten tables and can be found with this article online at doi:10.
1016/j.cell.2010.05.020.
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